Can finerenone (Kerendia) and empagliflozin (Jardiance) be used together to treat albuminuria in a type 2 diabetic patient already on an ACE inhibitor or ARB with eGFR ≥25 mL/min/1.73 m² and serum potassium ≤4.8 mmol/L?

Combining Kerendia (Finerenone) and Jardiance (Empagliflozin) for Albuminuria in Type 2 Diabetes

Yes, finerenone and empagliflozin should be used together in type 2 diabetic patients with albuminuria who are already on an ACE inhibitor or ARB, provided eGFR ≥25 mL/min/1.73 m² and serum potassium ≤4.8 mmol/L. This combination provides superior albuminuria reduction and cardiovascular-renal protection compared to either agent alone.

Evidence-Based Rationale for Combination Therapy

The 2022 ADA/KDIGO consensus guidelines explicitly recommend a layered approach: start with an ACE inhibitor or ARB as first-line therapy, add an SGLT2 inhibitor (like empagliflozin) for patients with eGFR ≥20 mL/min/1.73 m², and then add finerenone for those with persistent albuminuria (ACR ≥30 mg/g) despite maximum tolerated RAS inhibition 1. The 2023 AACE guidelines similarly endorse this strategy, noting that finerenone is recommended for persons with CKD associated with diabetes and eGFR ≥25 mL/min/1.73 m² and UACR ≥30 mg/g, with increased laboratory monitoring when combining ACEi/ARB with mineralocorticoid receptor antagonists 2.

The recent CONFIDENCE trial (2025) provides the strongest direct evidence: simultaneous initiation of finerenone plus empagliflozin reduced albuminuria by 29% more than finerenone alone and 32% more than empagliflozin alone at 180 days 3. This additive benefit was consistent across all KDIGO risk categories, from low/moderate risk (-61.7% UACR reduction) to very high risk (-52.4% reduction) 4.

Practical Implementation Algorithm

Step 1: Verify Eligibility Criteria

• eGFR ≥25 mL/min/1.73 m² (both drugs can be initiated) 1, 5, 6
• Serum potassium ≤4.8 mmol/L (per trial criteria) or ≤5.0 mmol/L (per FDA label) 1, 5, 6
• UACR ≥30 mg/g (finerenone indication) 1, 5
• Stable ACE inhibitor or ARB for ≥1 month at maximum tolerated dose 5

Step 2: Initiate Empagliflozin

• Start empagliflozin 10 mg once daily regardless of eGFR (effective down to eGFR 20 mL/min/1.73 m²) 7, 8
• Empagliflozin can be used for glycemic control when eGFR ≥30 mL/min/1.73 m², but for cardiovascular-renal protection, it's effective down to eGFR 20 mL/min/1.73 m² 7, 8
• Contraindicated in patients on dialysis 8

Step 3: Initiate Finerenone Based on eGFR

• eGFR >60 mL/min/1.73 m²: Start finerenone 20 mg once daily 1, 5, 6
• eGFR 25-60 mL/min/1.73 m²: Start finerenone 10 mg once daily 1, 5, 6
• eGFR <25 mL/min/1.73 m²: Do not initiate (but may continue if already on therapy with acceptable potassium) 1, 5, 6

Step 4: Mandatory Monitoring Protocol

• Check serum potassium at 4 weeks after initiation of finerenone 1, 5, 6
• Check serum potassium at 4 weeks after any dose adjustment 1, 5, 6
• Regular ongoing potassium monitoring throughout treatment 1, 5, 6
• Monitor eGFR periodically, especially in heart failure patients 6

Step 5: Dose Titration Based on Potassium

• Potassium <4.8 mmol/L: Uptitrate finerenone from 10 mg to 20 mg once daily 1, 5, 6
• Potassium ≤5.5 mmol/L: Continue current finerenone dose 1, 5, 6
• Potassium >5.5 mmol/L: Withhold finerenone; restart at 10 mg once daily when potassium ≤5.0 mmol/L 1, 5, 6

Safety Profile of Combination Therapy

The CONFIDENCE trial demonstrated that combination therapy did not significantly increase hyperkalemia risk compared to finerenone alone (15.1% with combination vs. 18.8% with finerenone alone vs. 9.7% with empagliflozin alone) 9. Importantly, hyperkalemia was not in the causal pathway of albuminuria reduction—the treatment effect was maintained regardless of whether hyperkalemia developed 9.

Acute kidney injury was uncommon across all treatment groups 3, 9. In patients with heart failure, worsening renal function occurred more frequently with finerenone (18% vs. 12% with placebo), but severe events requiring hospitalization were rare 6.

Treatment discontinuation due to hyperkalemia was low: only 1.7% with finerenone vs. 0.6% with placebo in the pooled FIDELIO-DKD and FIGARO-DKD trials 6. The CONFIDENCE trial showed few treatment discontinuations overall 9.

Critical Pitfalls to Avoid

1. Never use finerenone as monotherapy—it must always be combined with an ACE inhibitor or ARB 5
2. Never combine finerenone with other mineralocorticoid receptor antagonists (spironolactone, eplerenone) 5
3. Never skip the 4-week potassium check after initiation or dose adjustment 1, 5, 6
4. Do not automatically stop finerenone if eGFR falls below 25 mL/min/1.73 m²—continue if potassium remains controlled 1, 5, 6
5. Do not initiate finerenone if serum potassium >5.0 mmol/L 6
6. Do not combine ACE inhibitors with ARBs—this increases adverse events without additional benefit 1, 10

Cardiovascular and Renal Outcomes

Beyond albuminuria reduction, finerenone reduces the composite of cardiovascular death, nonfatal MI, nonfatal stroke, or hospitalization for heart failure in pooled analysis from FIDELIO-DKD and FIGARO-DKD 11. The 2025 ADA Standards recommend that for patients with type 2 diabetes and CKD with albuminuria treated with maximum tolerated ACEi/ARB, addition of finerenone should be considered to improve cardiovascular outcomes and reduce CKD progression 11.

Empagliflozin reduces cardiovascular and renal events in patients down to eGFR 30 mL/min/1.73 m², independent of glucose-lowering effects 7. The 2024 KDIGO guidelines recommend treating adults with type 2 diabetes, CKD, and eGFR ≥20 mL/min/1.73 m² with an SGLT2 inhibitor 12, 13.

Special Considerations

Baseline GLP-1 RA use does not affect efficacy or safety: In CONFIDENCE, the combination was effective and well-tolerated regardless of whether patients were using a GLP-1 receptor agonist at baseline 14. This is important because many patients with type 2 diabetes and CKD will be on triple therapy (RASi + SGLT2i + GLP-1 RA) before finerenone is added.

KDIGO risk category improvement: Finerenone therapy increases the likelihood of improving KDIGO risk category (OR 1.47 at month 36) and decreases the likelihood of worsening (OR 0.83), with category improvement associated with reduced cardiovascular events 15.